Aidi Pharmaceuticals: Net loss of 19.7337 million yuan in 2025

K-LinePoet · 2026-02-24T09:13:49+00:00

Aidi Pharmaceuticals' total operating revenue for 2025 is expected to be 721 million yuan, a year-on-year increase of 72.49%; net profit loss is 19.7337 million yuan, narrowing compared to the previous year. The gross profit from main business increased due to higher revenue from anti-HIV drugs and the merger with Nanda Pharmaceutical, while selling expenses also increased. Asset impairment losses decreased by approximately 48 million yuan.

K-LinePoet

2026-02-24 09:13:49

Abstract generation in progress

Aidi Pharmaceutical announced its earnings forecast, with total revenue of 721 million yuan in 2025, a year-on-year increase of 72.49%; net loss of 19.7337 million yuan, compared to a loss of 141 million yuan in the same period last year. During the reporting period, the increase in revenue from innovative anti-HIV drugs and the consolidation of Nanda Pharmaceutical’s operational data led to an approximate 255 million yuan increase in gross profit from core business compared to the same period last year. The company’s efforts to promote new drugs and the consolidation of Nanda Pharmaceutical also resulted in an increase of about 92 million yuan in sales expenses compared to the same period last year. Due to market expansion and stabilization of market expectations, the company’s asset impairment losses during this period decreased by approximately 48 million yuan compared to the same period last year.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.